NG
NervGen Pharma Corp. Common stock (NGEN)
NASDAQ·Healthcare·Biotechnology
$2.13
+6.25%
Mkt Cap $150.53M
Analyst Ratings
No recent rating data.
Price Target (1 analysts)
$12.00
Range $12.00 – $12.00
Implied Upside
+464.7%
Consensus $12.00 vs current $2.13